Cargando…

EMT is not required for lung metastasis but contributes to chemoresistance

The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Kari R., Durrans, Anna, Lee, Sharrell, Sheng, Jianting, Li, Fuhai, Wong, Stephen, Choi, Hyejin, El Rayes, Tina, Ryu, Seongho, Troeger, Juliane, Schwabe, Robert F., Vahdat, Linda T., Altorki, Nasser K., Mittal, Vivek, Gao, Dingcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662610/
https://www.ncbi.nlm.nih.gov/pubmed/26560033
http://dx.doi.org/10.1038/nature15748
Descripción
Sumario:The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models. We confirmed that within a predominantly epithelial primary tumor, a small portion of tumor cells undergo EMT. Strikingly, lung metastases mainly consisted of non-EMT tumor cells maintaining their epithelial phenotype. Inhibiting EMT by overexpressing miR-200 did not impact lung metastasis development. However, EMT cells significantly contribute to recurrent lung metastasis formation after chemotherapy. These cells survived cyclophosphamide treatment due to reduced proliferation, apoptotic tolerance, and elevated expression of chemoresistance-related genes. Overexpression of miR-200 abrogated this resistance. This study suggests the potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment.